Free Trial
LON:ONC

Oncimmune (ONC) Share Price, News & Analysis

Oncimmune logo
GBX 15.14 +0.04 (+0.26%)
(As of 10:38 AM ET)

About Oncimmune Stock (LON:ONC)

Key Stats

Today's Range
15.10
15.14
50-Day Range
12.51
24
52-Week Range
9.35
31
Volume
351,185 shs
Average Volume
124,567 shs
Market Capitalization
£11.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.

Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncimmune and its competitors with MarketBeat's FREE daily newsletter.

ONC Stock News Headlines

When it comes to NVDA… “acceleration cycles” are the key
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.
See More Headlines

ONC Stock Analysis - Frequently Asked Questions

Oncimmune's stock was trading at GBX 25.20 at the start of the year. Since then, ONC shares have decreased by 39.9% and is now trading at GBX 15.14.
View the best growth stocks for 2024 here
.

Oncimmune Holdings plc (LON:ONC) announced its quarterly earnings results on Tuesday, February, 13th. The company reported ($5.70) EPS for the quarter. The company had revenue of $0.08 million for the quarter. Oncimmune had a negative trailing twelve-month return on equity of 760.96% and a net margin of 586.08%.

Shares of ONC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncimmune investors own include B&M European Value Retail (BME), Coats Group (COA), 4D pharma (DDDD), genedrive (GDR), Greencore Group (GNC), Intel (INTC) and IQE (IQE).

Company Calendar

Last Earnings
2/13/2018
Today
11/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
52
Year Founded
N/A

Profitability

Net Income
£-3,140,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£1.21 million
Cash Flow
GBX 1.27 per share

Miscellaneous

Free Float
N/A
Market Cap
£11.22 million
Optionable
Not Optionable
Beta
1.19
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (LON:ONC) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners